pharmaceutical companies looking to save millions
of dollars, avoid regulatory scrutiny and tap into a seemingly endless supply
of drug study participants.
But a year-long Dateline investigation into one of the preferred destinations for overseas drug trials, India, raises questions about lax regulatory oversight in these studies, the integrity of some of the companies contracted to run them and the reliability of the data they produce. ......Dr.